Angiostatin™ and Endostatin™: Endothelial cell-specific endogenous inhibitors of angiogenesis and tumor growth

Angiogenesis

Volumn 2, Issue 1, 1998, Pages 37-48

  Sim, B Kim Lee ^a  

^a ENTREMED INC   (United States)

Author keywords

Angiostatin; Endostatin; Endothelial cell

Indexed keywords

MURINAE;

EID: 0003092713     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009050309715     Document Type: Review

References (47)

1. Fisher B, Gunduz N, Coyle J, Rudock C, Saffer E. Presence of a growth stimulating factor in serum following primary tumor removal in mice. Cancer Res 1989; 49, 1996-2001.
2. Gorelik E. Resistance of tumor-bearing mice to a second tumor challenge. Cancer Res 1983; 43, 138-145.
3. Prehn RT. The Inhibition of tumor growth by tumor mass. Cancer Res 1991; 51, 2-4.
4. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1, 27-31.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285, 1182-1186.
6. Folkman J. Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel MA, Liotta LA (eds), The Molecular Basis of Cancer. Philadelphia, PA: Saunders 1995: 206-232.
7. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1, 149-153.
8. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88, 277-285.
9. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79, 315-328.
10. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2, 689-692.
11. O'Reilly MS. Angiostatin: an endogenous inhibitor of angiogene of tumor growth. EXS 1997; 79, 273-294.
12. Chen C, Parangi S, Tolentino MJ, Folkman J. A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res 1995; 55, 4230-4233.
13. Ferrara N, Clapp C, Weiner RI. The 16K fragment of prolactin specifically inhibits basal or fibroblast growth factor stimulated growth of capillary endothelial cells. Endocrinology 1991; 129, 896-900.
14. Clapp C, Martial JA, Guzman RC, Rentier-Delrue F, Weiner RI. The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis. Endocrinology 1993; 133, 1292-1299.
15. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18, 4-25.
16. Saksela O. Plasminogen activation and regulation of pericellularproteolysis. Biochim Biophys Acta 1985; 823, 35-65.
17. Ponting CP, Marshall JM, Cederholm-Williams SA. Plasminogen: a structural review. Blood Coagulation and Fibrinolysis 1992; 3, 605-614.
18. Cao Y, Ji RW, Davidson D, et al. Kringle domains of human angiostatin: characterization of the anti-proliferation activity on endothelial cells. J Biol Chem 1996; 271, 29461-29467.
19. Dong Z, Kumar R, Yang X, Fidler IJ. Macrophage-derived metalloelastase is responsible for the generation of Angiostatin in Lewis Lung Carcinoma. Cell 1997; 88, 801-810.
20. Gately S, Twardowski P, Stack SM, et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, Angiostatin. Cancer Res 1996; 56, 4887-4890.
21. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF. Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 1991; 30, 1682-1691.
22. Felez J, Miles LA, Fabregas P, Jardi M, Plow EF, Lijnen RH. Characterization of cellular binding sites and interactive regions within reactants required for enhancement of plasminogen activation by tPA on the surface of leukocyte cells. Thromb Haemostat 1996; 76, 577-584.
23. Plow EF, Freaney DE, Plescia J, Miles LA. The plasminogen system and cell surfaces: Evidence for plasminogen and urokinase receptors on the same cell type. J Cell Biol 1986; 103, 2411-2420.
24. Miles LA, Plow EF. Binding and activation of plasminogen on the platelet surface. J Biol Chem 1985; 260, 4303-4311.
25. Hajjar KA, Jacovina AT, Chacko J. An endothelial cell receptor for plasminogen/tissue plasminogen activator. I. Identity with annexin II. J Biol Chem 1994; 33, 21191-21197.
26. Cesarman GM, Guevara CA, Hajjar KA. An endothelial cell receptor for plasminogen/Tissue plasminogen activator (t-PA). J Biol Chem 1994; 269, 21198-21203.
27. Miles LA, Dahlberg CM, Plow EF. The cell-binding domains of plasminogen and their function in plasma. J Biol Chem 1988; 263, 11928-11934.
28. Castellino FJ, Ploplis VA, Powell JR, Strickland DK. The existence of independent domain structures in human Lys77-plasminogen. J Biol Chem 1981; 256, 4778-4782.
29. Cao Y, Chen A, An SSA, et al. Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 1997; 272, 22924-22928.
30. Bannerman DD, Goldblum SE. Endotoxin induces endothelial barrier dysfunction through protein tyrosine phosphorylation. Am J Physiol 1997; 273, L217-226.
31. Melzig MF, Loose R. Investigations into the mechanism of toxicity of lipopolysaccharide (LPS) in bovine aortic endothelial cells. Pharmazie 1995; 50, 558-560.
32. Oh SK, Kamagata Y, Muragaki Y, Timmons S, Ooshima A, Olsen BR. Isolation and sequencing of cDNAs for proteins with multiple domains of gly-Xaa-Yaa repeats identify a distinct family of collagenous proteins. Proc Natl Acad Sci USA 1994; 91, 4229-4233.
33. Rehn M, Pihlajaniemi T. α1(XVIII), a collagen chain with frequent interruptions in the collagenous sequence, a distinct tissue distribution, and homology with type XV collagen. Proc Natl Acad Sci USA 1994; 91, 4234-4238.
34. Rehn M, Pihlajaniemi T. Identification of three N-terminal ends of type XVIII collagen chains and tissue-specific differences in the expression of the corresponding transcripts. J Biol Chem 1995; 270, 4705-4711.
35. Rehn M, Hintikka E, Pihlajaniemi T. Characterization of the mouse gene for the alpha 1 chain of type XVIII collagen (co118a1) reveals that the three variant N-terminal polypeptide forms are transcribed from two widely separated promoters. Genomics 1996; 32, 436-446.
36. Muragaki Y, Timmons S, Griffith CM, et al. Mouse Col18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones. Proc Natl Acad Sci USA 1995; 92, 8763-8767.
37. Sim BKL, O'Reilly MS, Liang H, et al. A recombinant human Angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res 1997; 57, 1329-1334.
38. Wu Z, O'Reilly MS, Folkman J, Shing Y. Suppression of tumor growth with recombinant murine angiostatin. Biochem Biophy Res Commun 1997; 236, 651-654.
39. Boehm T, Folkman J, Browder T, O'Reilly MS. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390, 404-407.
40. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285, 1182-1186.
41. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996; 32A, 2534-2539.
42. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333, 1757-1763.
43. Teicher BA, Holden SA, Ara G. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994; 57, 920-925.
44. Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med 1995; 1, 120-220.
45. Menendez AT, Laidlaw J, Raventos-Suarez C, Class K, Lee F, Kramer R. In vitro characterization of Angiostatin: Kinetics, cell cycle effects and cAMP activation in endothelial cells. Proc Am Ass Cancer Res 1997; abstr 1776.
46. Stathakis P, Fitzgerald M, Matthias LJ, Chesterman CH, Hogg PJ. Generation of angiostatin by reduction and proteolysis of plasmin. Catalysis by a plasmin reductase secreted by cultured cells. J Biol Chem 1997; 15, 20641-20645.
47. Shih GC, Hajjar KA. Plasminogen and plasminogen activator assembly and the human endothelial cell. Proc Soc Exp Biol Med 1993; 202, 258-264.